Search Results
You are looking at 1 - 5 of 5 items for
- Author: Rogelio García-Centeno x
- Refine by access: All content x
Department of Health Science, Universidad de Alcalá, Madrid, Spain
Search for other papers by Marta Araujo-Castro in
Google Scholar
PubMed
Search for other papers by Rogelio Garcia Centeno in
Google Scholar
PubMed
Search for other papers by María-Carmen López-García in
Google Scholar
PubMed
Search for other papers by Cristina Lamas in
Google Scholar
PubMed
Search for other papers by Cristina Álvarez-Escolá in
Google Scholar
PubMed
Search for other papers by María Calatayud Gutiérrez in
Google Scholar
PubMed
Search for other papers by Concepción Blanco-Carrera in
Google Scholar
PubMed
Search for other papers by Paz de Miguel Novoa in
Google Scholar
PubMed
Search for other papers by Nuria Valdés in
Google Scholar
PubMed
Search for other papers by Paola Gracia Gimeno in
Google Scholar
PubMed
Search for other papers by Mariana Tomé Fernández-Ladreda in
Google Scholar
PubMed
Search for other papers by César Mínguez Ojeda in
Google Scholar
PubMed
Search for other papers by Juan Carlos Percovich Hualpa in
Google Scholar
PubMed
Group of Endocrine Disorders, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
Search for other papers by Mireia Mora in
Google Scholar
PubMed
Search for other papers by Óscar Vidal in
Google Scholar
PubMed
Search for other papers by Ana Serrano Romero in
Google Scholar
PubMed
Group of Endocrine Disorders, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
Search for other papers by Felicia Alexandra Hanzu in
Google Scholar
PubMed
Search for other papers by Victoria Gómez Dos Santos in
Google Scholar
PubMed
We aimed to identify presurgical and surgical risk factors for intraoperative complications in patients with pheochromocytomas. A retrospective study of patients with pheochromocytomas who underwent surgery in ten Spanish hospitals between 2011 and 2021 was performed. One hundred and sixty-two surgeries performed in 159 patients were included. The mean age was 51.6 ± 16.4 years old and 52.8% were women. Median tumour size was 40 mm (range 10–110). Laparoscopic adrenalectomy was performed in 148 patients and open adrenalectomy in 14 patients. Presurgical alpha- and beta-blockade was performed in 95.1% and 51.9% of the surgeries, respectively. 33.3% of the patients (n = 54) had one or more intraoperative complications. The most common complication was the hypertensive crisis in 21.0%, followed by prolonged hypotension in 20.0%, and hemodynamic instability in 10.5%. Patients pre-treated with doxazosin required intraoperative hypotensive treatment more commonly than patients pre-treated with other antihypertensive drugs (51.1% vs 26.5%, P = 0.002). Intraoperative complications were more common in patients with higher levels of urine metanephrine (OR = 1.01 for each 100 μg/24 h, P = 0.026) and normetanephrine (OR = 1.00 for each 100 μg/24 h, P = 0.025), larger tumours (OR = 1.4 for each 10 mm, P < 0.001), presurgical blood pressure > 130/80 mmHg (OR = 2.25, P = 0.027), pre-treated with doxazosin (OR = 2.20, P = 0.023) and who had not received perioperative hydrocortisone (OR = 3.95, P = 0.008). In conclusion, intraoperative complications in pheochromocytoma surgery are common and can be potentially life-threatening. Higher metanephrine and normetanephrine levels, larger tumour size, insufficient blood pressure control before surgery, pre-treatment with doxazosin, and the lack of treatment with perioperative hydrocortisone are associated with higher risk of intraoperative complications.
Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Madrid, Spain
University of Alcalá, Madrid, Spain
Search for other papers by Marta Araujo-Castro in
Google Scholar
PubMed
Search for other papers by César Mínguez Ojeda in
Google Scholar
PubMed
Search for other papers by Rogelio García Centeno in
Google Scholar
PubMed
Search for other papers by María-Carmen López-García in
Google Scholar
PubMed
Search for other papers by Cristina Lamas in
Google Scholar
PubMed
Search for other papers by Felicia Alexandra Hanzu in
Google Scholar
PubMed
Search for other papers by Mireia Mora in
Google Scholar
PubMed
Search for other papers by María del Castillo Tous in
Google Scholar
PubMed
Search for other papers by Pablo Rodríguez de Vera Gómez in
Google Scholar
PubMed
Search for other papers by Paola Parra Ramírez in
Google Scholar
PubMed
Search for other papers by Cristina Alvarez-Escola in
Google Scholar
PubMed
Search for other papers by Concepción Blanco Carrera in
Google Scholar
PubMed
Search for other papers by Rebeca Barahona San Millán in
Google Scholar
PubMed
Search for other papers by Mónica Recasens in
Google Scholar
PubMed
Search for other papers by Nuria Valdés in
Google Scholar
PubMed
Search for other papers by Paola Gracia Gimeno in
Google Scholar
PubMed
Search for other papers by Paz de Miguel Novoa in
Google Scholar
PubMed
Search for other papers by Almudena Vicente in
Google Scholar
PubMed
Instituto de Investigación Sanitaria del Principado de Asturias (ISPA)
Search for other papers by Laura Manjón in
Google Scholar
PubMed
Search for other papers by Iñigo García Sanz in
Google Scholar
PubMed
Search for other papers by Theodora Michalopoulou in
Google Scholar
PubMed
Search for other papers by María Calatayud in
Google Scholar
PubMed
The objective of our study was to determine the prevalence of glycemic disorders (diabetes mellitus and prediabetes) in patients with pheochromocytomas and sympathetic paragangliomas (PPGLs) and identify risk factors for their development and the likelihood of their resolution after surgery. A multicentric retrospective study of patients with PPGLs submitted to surgery between 2000 and 2021 in 17 Spanish hospitals was performed. Diabetes-specific data were collected at diagnosis, in the immediate- and long-term postsurgical follow-up. A total of 229 patients with PPGLs were included (218 with pheochromocytomas and 11 with sympathetic paragangliomas). Before surgery, glycemic disorders were diagnosed in 35.4% of the patients (n = 81): 54 with diabetes and 27 with prediabetes. The variables independently associated with a higher risk of glycemic disorders were sporadic PPGL (odds ratio (OR) = 3.26 (1.14–9.36)) and hypertension (OR = 3.14 (1.09–9.01)). A significant decrease in fasting plasma glucose and HbA1c levels was observed after surgery, in the short-term and long-term follow-up (P < 0.001). After a median follow-up of 48.5 months (range 3.3–168.9), after surgery, 52% of diabetic and 68% of prediabetic patients experienced a complete resolution. Lower body mass index (BMI) (P = 0.001), lower glucose levels (P = 0.047) and shorter duration of diabetes prior to surgery (P = 0.021) were associated with a higher probability of diabetes resolution. In conclusion, glycemic disorders in patients with PPGLs are present in more than a third of them at diagnosis. Sporadic PPGLs and hypertension are risk factors for their development. More than 50% of cases experience a complete resolution of the glycemic disorder after resection of the PPGLs.
Search for other papers by Iulia Potorac in
Google Scholar
PubMed
Search for other papers by Patrick Petrossians in
Google Scholar
PubMed
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Search for other papers by Orsalia Alexopoulou in
Google Scholar
PubMed
Search for other papers by Sophie Borot in
Google Scholar
PubMed
Search for other papers by Mona Sahnoun-Fathallah in
Google Scholar
PubMed
Search for other papers by Frederic Castinetti in
Google Scholar
PubMed
Search for other papers by France Devuyst in
Google Scholar
PubMed
Search for other papers by Marie-Lise Jaffrain-Rea in
Google Scholar
PubMed
Search for other papers by Claire Briet in
Google Scholar
PubMed
Search for other papers by Florina Luca in
Google Scholar
PubMed
Search for other papers by Marion Lapoirie in
Google Scholar
PubMed
Search for other papers by Flavius Zoicas in
Google Scholar
PubMed
Search for other papers by Isabelle Simoneau in
Google Scholar
PubMed
Search for other papers by Alpha M Diallo in
Google Scholar
PubMed
Search for other papers by Ammar Muhammad in
Google Scholar
PubMed
Search for other papers by Fahrettin Kelestimur in
Google Scholar
PubMed
Search for other papers by Elena Nazzari in
Google Scholar
PubMed
Search for other papers by Rogelio Garcia Centeno in
Google Scholar
PubMed
Search for other papers by Susan M Webb in
Google Scholar
PubMed
Search for other papers by Marie-Laure Nunes in
Google Scholar
PubMed
Search for other papers by Vaclav Hana in
Google Scholar
PubMed
Search for other papers by Véronique Pascal-Vigneron in
Google Scholar
PubMed
Search for other papers by Irena Ilovayskaya in
Google Scholar
PubMed
Search for other papers by Farida Nasybullina in
Google Scholar
PubMed
Search for other papers by Samia Achir in
Google Scholar
PubMed
Search for other papers by Diego Ferone in
Google Scholar
PubMed
Search for other papers by Sebastian J C M M Neggers in
Google Scholar
PubMed
Search for other papers by Brigitte Delemer in
Google Scholar
PubMed
Search for other papers by Jean-Michel Petit in
Google Scholar
PubMed
Search for other papers by Christof Schöfl in
Google Scholar
PubMed
Search for other papers by Gerald Raverot in
Google Scholar
PubMed
Search for other papers by Bernard Goichot in
Google Scholar
PubMed
Search for other papers by Patrice Rodien in
Google Scholar
PubMed
Search for other papers by Bernard Corvilain in
Google Scholar
PubMed
Search for other papers by Thierry Brue in
Google Scholar
PubMed
Search for other papers by Franck Schillo in
Google Scholar
PubMed
Search for other papers by Luaba Tshibanda in
Google Scholar
PubMed
Search for other papers by Dominique Maiter in
Google Scholar
PubMed
Search for other papers by Jean-François Bonneville in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
GH-secreting pituitary adenomas can be hypo-, iso- or hyper-intense on T2-weighted MRI sequences. We conducted the current multicenter study in a large population of patients with acromegaly to analyze the relationship between T2-weighted signal intensity on diagnostic MRI and hormonal and tumoral responses to somatostatin analogs (SSA) as primary monotherapy. Acromegaly patients receiving primary SSA for at least 3 months were included in the study. Hormonal, clinical and general MRI assessments were performed and assessed centrally. We included 120 patients with acromegaly. At diagnosis, 84, 17 and 19 tumors were T2-hypo-, iso- and hyper-intense, respectively. SSA treatment duration, cumulative and mean monthly doses were similar in the three groups. Patients with T2-hypo-intense adenomas had median SSA-induced decreases in GH and IGF-1 of 88% and 59% respectively, which were significantly greater than the decreases observed in the T2-iso- and hyper-intense groups (P < 0.001). Tumor shrinkage on SSA was also significantly greater in the T2-hypo-intense group (38%) compared with the T2-iso- and hyper-intense groups (8% and 3%, respectively; P < 0.0001). The response to SSA correlated with the calculated T2 intensity: the lower the T2-weighted intensity, the greater the decrease in random GH (P < 0.0001, r = 0.22), IGF-1 (P < 0.0001, r = 0.14) and adenoma volume (P < 0.0001, r = 0.33). The T2-weighted signal intensity of GH-secreting adenomas at diagnosis correlates with hormone reduction and tumor shrinkage in response to primary SSA treatment in acromegaly. This study supports its use as a generally available predictive tool at diagnosis that could help to guide subsequent treatment choices in acromegaly.
Search for other papers by Marta Araujo-Castro in
Google Scholar
PubMed
Search for other papers by Betina Biagetti in
Google Scholar
PubMed
Search for other papers by Edelmiro Menéndez Torre in
Google Scholar
PubMed
Search for other papers by Iría Novoa-Testa in
Google Scholar
PubMed
Search for other papers by Fernando Cordido in
Google Scholar
PubMed
Search for other papers by Eider Pascual-Corrales in
Google Scholar
PubMed
Search for other papers by Víctor Rodríguez Berrocal in
Google Scholar
PubMed
Search for other papers by Fernando Guerrero-Pérez in
Google Scholar
PubMed
Search for other papers by Almudena Vicente in
Google Scholar
PubMed
Search for other papers by Juan Carlos Percovich Hualpa in
Google Scholar
PubMed
Search for other papers by Rogelio García-Centeno in
Google Scholar
PubMed
Search for other papers by Laura González-Fernández in
Google Scholar
PubMed
Search for other papers by María Dolores Ollero García in
Google Scholar
PubMed
Search for other papers by Ana Irigaray Echarri in
Google Scholar
PubMed
Search for other papers by María Dolores Moure Rodríguez in
Google Scholar
PubMed
Search for other papers by Cristina Novo-Rodríguez in
Google Scholar
PubMed
Search for other papers by María Calatayud in
Google Scholar
PubMed
Search for other papers by Rocío Villar-Taibo in
Google Scholar
PubMed
Search for other papers by Ignacio Bernabéu in
Google Scholar
PubMed
Search for other papers by Cristina Alvarez-Escola in
Google Scholar
PubMed
Search for other papers by Pamela Benítez Valderrama in
Google Scholar
PubMed
Search for other papers by Carmen Tenorio-Jiménez in
Google Scholar
PubMed
Department of Medicine and Surgery, Universidad Cardenal Herrera-CEU, CEU Universities, Castellón, Spain
Search for other papers by Pablo Abellán Galiana in
Google Scholar
PubMed
Search for other papers by Eva Venegas in
Google Scholar
PubMed
Search for other papers by Inmaculada González-Molero in
Google Scholar
PubMed
Search for other papers by Pedro Iglesias in
Google Scholar
PubMed
Search for other papers by Concepción Blanco-Carrera in
Google Scholar
PubMed
Search for other papers by Fernando Vidal-Ostos De Lara in
Google Scholar
PubMed
Search for other papers by Paz de Miguel Novoa in
Google Scholar
PubMed
Search for other papers by Elena López Mezquita in
Google Scholar
PubMed
Search for other papers by Felicia Alexandra Hanzu in
Google Scholar
PubMed
Neurological Tissue Bank of the Biobank, FCRB-IDIBAPS-Hospital Clinic Barcelona, Barcelona, Spain
Search for other papers by Iban Aldecoa in
Google Scholar
PubMed
Search for other papers by Silvia Aznar in
Google Scholar
PubMed
Search for other papers by Cristina Lamas in
Google Scholar
PubMed
Department of Medicine, Universitat de Vic-Universitat Central de Catalunya, Vic, Spain
Search for other papers by Anna Aulinas in
Google Scholar
PubMed
Department of Medicine, Universitat de Vic-Universitat Central de Catalunya, Vic, Spain
Search for other papers by Queralt Asla in
Google Scholar
PubMed
Search for other papers by Paola Gracia Gimeno in
Google Scholar
PubMed
Search for other papers by José María Recio-Córdova in
Google Scholar
PubMed
Search for other papers by María Dolores Avilés-Pérez in
Google Scholar
PubMed
Search for other papers by Diego Asensio-Wandosell in
Google Scholar
PubMed
Search for other papers by Miguel Sampedro-Núñez in
Google Scholar
PubMed
Search for other papers by Rosa Cámara in
Google Scholar
PubMed
Search for other papers by Miguel Paja Fano in
Google Scholar
PubMed
Search for other papers by Ignacio Ruz-Caracuel in
Google Scholar
PubMed
Search for other papers by Carmen Fajardo in
Google Scholar
PubMed
Search for other papers by Mónica Marazuela in
Google Scholar
PubMed
Search for other papers by Manel Puig-Domingo in
Google Scholar
PubMed
Search for other papers by Marta Araujo-Castro in
Google Scholar
PubMed
Search for other papers by Betina Biagetti in
Google Scholar
PubMed
Search for other papers by Edelmiro Menéndez Torre in
Google Scholar
PubMed
Search for other papers by Iría Novoa-Testa in
Google Scholar
PubMed
Search for other papers by Fernando Cordido in
Google Scholar
PubMed
Search for other papers by Eider Pascual-Corrales in
Google Scholar
PubMed
Search for other papers by Víctor Rodríguez Berrocal in
Google Scholar
PubMed
Search for other papers by Fernando Guerrero-Pérez in
Google Scholar
PubMed
Search for other papers by Almudena Vicente in
Google Scholar
PubMed
Search for other papers by Juan Carlos Percovich Hualpa in
Google Scholar
PubMed
Search for other papers by Rogelio García-Centeno in
Google Scholar
PubMed
Search for other papers by Laura González-Fernández in
Google Scholar
PubMed
Search for other papers by María Dolores Ollero García in
Google Scholar
PubMed
Search for other papers by Ana Irigaray Echarri in
Google Scholar
PubMed
Search for other papers by María Dolores Moure Rodríguez in
Google Scholar
PubMed
Search for other papers by Cristina Novo-Rodríguez in
Google Scholar
PubMed
Search for other papers by María Calatayud in
Google Scholar
PubMed
Search for other papers by Rocío Villar-Taibo in
Google Scholar
PubMed
Search for other papers by Ignacio Bernabéu in
Google Scholar
PubMed
Search for other papers by Cristina Alvarez-Escola in
Google Scholar
PubMed
Search for other papers by Pamela Benítez Valderrama in
Google Scholar
PubMed
Search for other papers by Carmen Tenorio-Jiménez in
Google Scholar
PubMed
Department of Medicine and Surgery, Universidad Cardenal Herrera-CEU, CEU Universities, Castellón, Spain
Search for other papers by Pablo Abellán Galiana in
Google Scholar
PubMed
Search for other papers by Eva Venegas in
Google Scholar
PubMed
Search for other papers by Inmaculada González-Molero in
Google Scholar
PubMed
Search for other papers by Pedro Iglesias in
Google Scholar
PubMed
Search for other papers by Concepción Blanco-Carrera in
Google Scholar
PubMed
Search for other papers by Fernando Vidal-Ostos De Lara in
Google Scholar
PubMed
Search for other papers by Paz de Miguel Novoa in
Google Scholar
PubMed
Search for other papers by Elena López Mezquita in
Google Scholar
PubMed
Search for other papers by Felicia Alexandra Hanzu in
Google Scholar
PubMed
Neurological Tissue Bank of the Biobank, FCRB-IDIBAPS-Hospital Clinic Barcelona, Barcelona, Spain
Search for other papers by Iban Aldecoa in
Google Scholar
PubMed
Search for other papers by Silvia Aznar in
Google Scholar
PubMed
Search for other papers by Cristina Lamas in
Google Scholar
PubMed
Department of Medicine, Universitat de Vic-Universitat Central de Catalunya, Vic, Spain
Search for other papers by Anna Aulinas in
Google Scholar
PubMed
Department of Medicine, Universitat de Vic-Universitat Central de Catalunya, Vic, Spain
Search for other papers by Queralt Asla in
Google Scholar
PubMed
Search for other papers by Paola Gracia Gimeno in
Google Scholar
PubMed
Search for other papers by José María Recio-Córdova in
Google Scholar
PubMed
Search for other papers by María Dolores Avilés-Pérez in
Google Scholar
PubMed
Search for other papers by Diego Asensio-Wandosell in
Google Scholar
PubMed
Search for other papers by Miguel Sampedro-Núñez in
Google Scholar
PubMed
Search for other papers by Rosa Cámara in
Google Scholar
PubMed
Search for other papers by Miguel Paja Fano in
Google Scholar
PubMed
Search for other papers by Ignacio Ruz-Caracuel in
Google Scholar
PubMed
Search for other papers by Carmen Fajardo in
Google Scholar
PubMed
Search for other papers by Mónica Marazuela in
Google Scholar
PubMed
Search for other papers by Manel Puig-Domingo in
Google Scholar
PubMed
The objective of the study was to evaluate the efficacy of second-line therapies in patients with acromegaly caused by a growth hormone (GH) and prolactin (PRL) co-secreting pituitary neuroendocrine tumor (GH&PRL-Pit-NET) compared to their efficacy in patients with acromegaly caused by a GH-secreting pituitary neuroendocrine tumor (GH-Pit-NET). This is a multicenter retrospective study of patients with acromegaly on treatment with pasireotide and/or pegvisomant. Patients were classified in two groups: GH&PRL-Pit-NETs when evidence of hyperprolactinemia and immunohistochemistry (IHC) for GH and PRL was positive or if PRL were >200 ng/dL regardless of the PRL-IHC and GH-Pit-NETs when the previously mentioned criteria were not met. A total of 28 cases with GH&PRL-Pit-NETs and 122 with GH-Pit-NETs met the inclusion criteria. GH&PRL-Pit-NETs presented at a younger age, caused hypopituitarism, and were invasive more frequently than GH-Pit-NETs. There were 124 patients treated with pegvisomant and 49 with pasireotide at any time. The efficacy of pegvisomant for IGF-1 normalization was of 81.5% and of pasireotide of 71.4%. No differences in IGF-1 control with pasireotide and with pegvisomant were observed between GH&PRL-Pit-NETs and GH-Pit-NETs. All GH&PRL-Pit-NET cases treated with pasireotide (n = 6) and 82.6% (n = 19/23) of the cases treated with pegvisomant normalized PRL levels. No differences in the rate of IGF-1 control between pegvisomant and pasireotide were detected in patients with GH&PRL-Pit-NETs (84.9% vs 66.7%, P = 0.178). We conclude that despite the more aggressive behavior of GH&PRL-Pit-NETs than GH-Pit-NETs, no differences in the rate of IGF-1 control with pegvisomant and pasireotide were observed between both groups, and both drugs have shown to be effective treatments to control IGF-1 and PRL hypersecretion in these tumors.